Dosage of Teli 40/Teli 80 in details
Teli 40/Teli 80 Dosage
Generic name: Teli 40/Teli 80 20mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
2.1 Hypertension
Dosage must be individualized. The usual starting dose of Teli 40/Teli 80 tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg.
Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Teli 40/Teli 80 is required, a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
Teli 40/Teli 80 tablets may be administered with other antihypertensive agents.
Teli 40/Teli 80 tablets may be administered with or without food.
2.2 Cardiovascular Risk Reduction
The recommended dose of Teli 40/Teli 80 tablets is 80 mg once a day and can be administered with or without food. It is not known whether doses lower than 80 mg of Teli 40/Teli 80 are effective in reducing the risk of cardiovascular morbidity and mortality.
When initiating Teli 40/Teli 80 therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
More about Teli 40/Teli 80 (Teli 40/Teli 80)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 25 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Teli 40/Teli 80
- Teli 40/Teli 80 (Advanced Reading)
Professional resources
- Teli 40/Teli 80 (AHFS Monograph)
- Teli 40/Teli 80 (FDA)
Other formulations
- Teli 40/Teli 80 HCT
Related treatment guides
- Cardiovascular Risk Reduction
- High Blood Pressure
- Prevention of Cardiovascular Disease
What other drugs will affect Teli 40/Teli 80?
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Teli 40/Teli 80, especially:
-
digoxin;
-
lithium;
-
a diuretic or "water pill";
-
NSAIDs (non-steroidal anti-inflammatory drugs)--aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, or meloxicam, and others; or
-
ramipril or other blood pressure medicines.
This list is not complete. Other drugs may interact with Teli 40/Teli 80, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Teli 40/Teli 80 interactions
Aliskiren: Do not co-administer aliskiren with Teli 40/Teli 80 in patients with diabetes. Avoid use of aliskiren with Teli 40/Teli 80 in patients with renal impairment (GFR < 60 mL/min).
Digoxin: When Teli 40/Teli 80 was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing Teli 40/Teli 80 for the purpose of keeping the digoxin level within the therapeutic range.
Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including Teli 40/Teli 80. Therefore, monitor serum lithium levels during concomitant use.
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Teli 40/Teli 80, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Teli 40/Teli 80 and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Teli 40/Teli 80 may be attenuated by NSAIDs including selective COX-2 inhibitors.
Ramipril and Ramiprilat: Co-administration of Teli 40/Teli 80 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3-and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4-and 1.5-fold, respectively. In contrast, Cmax and AUC of Teli 40/Teli 80 decrease by 31% and 16%, respectively. When co-administering Teli 40/Teli 80 and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of Teli 40/Teli 80. Concomitant use of Teli 40/Teli 80 and ramipril is not recommended.
Other Drugs: Co-administration of Teli 40/Teli 80 did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Teli 40/Teli 80 is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Teli 40/Teli 80 is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
References
- DailyMed. "AMLODIPINE BESYLATE; TELMISARTAN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "U5SYW473RQ: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Angiotensin II Type 1 Receptor Blockers". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Teli 40/Teli 80 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Teli 40/Teli 80. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
